Olaparib is the first PARP inhibitor approved in China for first-line maintenance treatment of germline and somatic BRCA mutated gynecological cancers.
The approval is based on a Phase III trial showing that Tecentriq significantly improved survival in patients with metastatic non-small cell lung cancer.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
